Charles River Laboratories International

Charles River Laboratories is a global preclinical and clinical contract research organization (CRO) and life-sciences services company, providing research models, preclinical safety and efficacy services, and clinical development support to pharma and biotech customers worldwide. As a strategic investor, Charles River participates in venture deals through corporate development and partnership structures, focused on companies that complement or extend their service portfolio — AI-driven drug discovery, animal model alternatives, in silico tools, lab automation, and translational platforms. For healthcare AI founders, Charles River is the right strategic counterparty if your platform plausibly fits inside their CRO services architecture, accelerates customer drug development, or enables a service offering Charles River could deliver to its pharma client base. Investment structures are typically partnership-led with equity components, with capital deployment plausibly $1M to $20M depending on the strategic fit and stage. Stage focus is flexible but skews to companies with validated technical milestones. Founders who should approach: AI-driven drug discovery platforms, in silico toxicology tools, lab automation, organoid and complex in vitro models, and translational software that pharma customers would buy through a CRO channel. Founders who should not approach: pure provider-side digital health, consumer health, and any platform that does not plausibly fit the CRO services architecture. Entry path is through Charles River Business Development, scientific KOLs in their network, or biotech VCs that co-invest with Charles River. Be prepared for a partnership-first conversation — equity often follows a successful service or licensing relationship, not the other way around.